e-learning
resources
Virtual 2020
Pre-Congress Content
Clinical studies of COPD: combination inhalers and much more
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort
H. Worth (Fürth, Germany), R. Buhl (Mainz, Germany), P. Kardos (Frankfurt, Germany), V. Obermoser (Nürnberg, Germany), E. Gückel (Nürnberg, Germany), C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany)
Source:
Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Session:
Clinical studies of COPD: combination inhalers and much more
Session type:
E-poster session
Number:
989
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Worth (Fürth, Germany), R. Buhl (Mainz, Germany), P. Kardos (Frankfurt, Germany), V. Obermoser (Nürnberg, Germany), E. Gückel (Nürnberg, Germany), C. Vogelmeier (Marburg, Germany), C. Criée (Bovenden, Germany). Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort. 989
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses
Source: International Congress 2017 – COPD management
Year: 2017
Compliance of pharmacotherapy with GOLD-guidelines: a longitudinal study in patients with COPD
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020
Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
The IMPACT of triple
versus
dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018
Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study
Source: International Congress 2018 – Eosinophils in airway disease
Year: 2018
Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD
Source: International Congress 2017 – COPD management
Year: 2017
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Triple therapy
versus
single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018
Year: 2018
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
Source: International Congress 2018 – COPD management
Year: 2018
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018
Anti-inflammatory asthma therapy adherence in paediatric patients: The PACMAN cohort study
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept